Indication
Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with activating mutations of EGFR TK.
Loading your page…
Loading your page…
Carcinoma, Non-Small-Cell Lung
Marketing Authorisation Holder: Mylan Pharmaceuticals Limited
EMA Authorisation: 27/09/2018
INN: gefitinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Gefitinib Mylan: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.